Akero Therapeutics
Akero Therapeutics, a biotech company focused on metabolic diseases, is seeking a Senior Program Director of Regulatory & Clinical Development to lead and execute clinical programs and portfolios, ensuring strategic alignment, governance, and operational excellence. The role involves collaboration across multiple departments and external partners to drive transformational growth and innovation.
Headquarters
South San Francisco, California, United States
Company Size
11-50 employees
Founded
2017
Akero Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformational therapies for metabolic dysfunction‑associated steatohepatitis (MASH) and related metabolic diseases. Their lead investigational candidate, efruxifermin (EFX), is an engineered FGF21‑based therapy designed to improve metabolic health and reduce liver disease in people with MASH. Akero advances programs through clinical development with the goal of addressing underlying metabolic drivers of liver disease and improving long‑term patient outcomes.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Akero Therapeutics.
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
Oct 14, 2025
Vice President, Clinical Operations
Alkeus Pharmaceuticals
Associate Director, Clinical Quality Assurance
Dyne Therapeutics
Senior Medical Director, Translational Medicine & Early Clinical Development
Madrigal Pharmaceuticals
Executive Director, Investor Relations
Entrada Therapeutics
Senior Medical Director Clinical Research Hepatology United Kingdom
alnylam
Vice President, Program and Portfolio Management
Septerna